# A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

> **NCT05186051** · PHASE2 · COMPLETED · sponsor: **Zydus Lifesciences Limited** · enrollment: 3 (actual)

## Conditions studied

- Cryopyrin Associated Periodic Syndrome

## Interventions

- **DRUG:** ZYIL1 capsule

## Key facts

- **NCT ID:** NCT05186051
- **Lead sponsor:** Zydus Lifesciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2022-07-02
- **Final completion:** 2022-07-02
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186051, "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05186051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*